Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
25.7% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
21
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
25.2% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
4
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.1% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
3
users have liked this narrative
1
users have commented on this narrative
10
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Treace Medical Concepts
AN
AnalystConsensusTarget
Consensus Narrative from 6 Analysts
New Bunion Treatments Will Open Broader Market Opportunities
Key Takeaways Innovative products and expanded portfolio aim to penetrate the U.S. bunion market and enhance revenue through increased surgeon adoption and market appeal. Operational leverage and new reimbursement policies are expected to boost earnings and promote adjusted EBITDA break-even by 2025.
View narrative
US$8.35
FV
21.8% undervalued
intrinsic discount
9.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
Updated
narrative
Guild Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Customer-for-Life Approach And AI Investments Will Expand Market Share In Financial Sector
Key Takeaways Effective cost management and strategic acquisitions bolster profitability and earnings, supported by a growing retail loan officer network and low market penetration. Investments in technology and AI initiatives enhance operational efficiency and customer experience, driving revenue growth and improving profitability.
View narrative
US$19.50
FV
3.4% overvalued
intrinsic discount
14.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
Updated
narrative
DNA
Ginkgo Bioworks Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Biopharma Demand Will Boost Automation And Data Services
Key Takeaways Shifting towards tools like Ginkgo Automation platform addresses biopharma AI data demand, enhancing revenue through diversification. Expanding customer base and government partnerships in Cell Engineering and Biosecurity aim for sustained revenue growth.
View narrative
US$10.33
FV
11.9% overvalued
intrinsic discount
-9.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
48
users have followed this narrative
Updated
narrative
Iovance Biotherapeutics
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
US Launch And Global Expansion Will Create New Opportunities
Key Takeaways The U.S. launch of Amtagvi and international expansion could drive significant revenue and market growth, enhancing revenue streams and market share. Manufacturing capacity improvements and economies of scale aim to boost gross margins and profitability significantly.
View narrative
US$9.10
FV
75.5% undervalued
intrinsic discount
45.53%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
58
users have followed this narrative
Updated
narrative
ANI Pharmaceuticals
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
ILUVIEN And YUTIQ Will Expand Market Use After Positive Trial Results In 2025
Key Takeaways Acquisition of Alimera and expansion in ophthalmology strengthen ANI's portfolio, boosting future sales and market presence. New product launches and clinical trial successes poised to drive revenue growth and improve net margins.
View narrative
US$85.75
FV
3.0% overvalued
intrinsic discount
8.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
Updated
narrative
Pagaya Technologies
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
Advanced AI Underwriting And Embedded Finance Will Open Markets
Key Takeaways Ongoing product expansion and new bank partnerships are driving greater revenue diversification, smoother growth, and increased market opportunity across financial service verticals. Advancements in AI-driven underwriting, combined with financing optimization, enhance profitability and cash flow, enabling scalable growth and continued investment.
View narrative
US$38.00
FV
17.0% undervalued
intrinsic discount
17.08%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
37
users have followed this narrative
Updated
narrative
Kratos Defense & Security Solutions
AN
AnalystConsensusTarget
Consensus Narrative from 14 Analysts
MACH-TB Hypersonic Contract And Defense Budgets Will Create Future Opportunities
Key Takeaways Defense budget increases and strategic contracts position Kratos for significant future revenue growth and enhanced earnings potential. Renewing contracts at higher rates and partnerships with firms like RAFAEL offer pathways to improved margins and earnings expansion.
View narrative
US$64.46
FV
7.3% overvalued
intrinsic discount
18.99%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
1
users have commented on this narrative
57
users have followed this narrative
Updated
narrative
Ascendis Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 16 Analysts
Upcoming SKYTROFA And YORVIPATH Launches Will Expand Global Reach
Key Takeaways Expanding product offerings and market reach, especially through SKYTROFA and YORVIPATH, aims to boost revenue and capture new opportunities. Strong cash reserves enable investment in product development and expansions, potentially leading to diversified revenue and improved margins.
View narrative
US$250.41
FV
21.7% undervalued
intrinsic discount
62.87%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
Updated
narrative
NuScale Power
AN
AnalystConsensusTarget
Consensus Narrative from 10 Analysts
RoPower SMR Technology Will Accelerate Manufacturing And Deployment
Key Takeaways NuScale's advanced SMR commercialization and partnerships position it well for accelerated revenue growth and immediate deployment in competitive energy markets. Efficiency improvements and strategic focus on reducing expenses are expected to enhance profitability and support margin expansion.
View narrative
US$40.73
FV
6.3% undervalued
intrinsic discount
104.12%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
1
users have commented on this narrative
104
users have followed this narrative
Updated
narrative
Value any company in seconds
Popular companies